Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Qiagen and Novartis announce companion diagnostics collaboration

Qiagen and Novartis announce companion diagnostics collaboration

13th November 2014

Qiagen is allying with Novartis on the development of companion diagnostics to accompany Novartis pharmaceutical products.

The master collaboration agreement with the Swiss pharmaceutical company will enable the development and commercialisation of companion diagnostics to be paired with existing Novartis pharmaceutical products, as well as compounds in its development pipeline.

It marks the ninth such master framework agreement reached by Qiagen for the development of companion diagnostics, highlighting its position as a preferred development partner for pharmaceutical companies.

This also reflects the growing importance of personalised treatment strategies based on genomic insights, allowing clinicians to select the right drug for the patient, at the right time and in the correct dose.

Peer Schatz, chief executive officer of Qiagen, said: "This broad agreement gives Novartis and Qiagen the flexibility to pursue co-development projects. We are committed to working with our partners like Novartis to make improvements in life possible."

It follows on from the agreement of a similar partnership with Astellas last month.ADNFCR-8000103-ID-801760066-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.